Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: * Luminal A subtype: Hormone receptor positive (progesterone and estrogen) and HER2 (ERBB2) negative * Luminal B subtype: Hormone receptor positive (progesterone and estrogen) and HER2 (ERBB2) positive * HER2 positive: Hormone receptor negative (progesterone and estrogen) and HER2 (ERBB2) positive * Basal-like or triple-negative (TNBCs): Hormone receptor negative (progesterone and estrogen) and HER2 (ERBB2) negative Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumors, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signaling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers. Phosphorylation sites were added based on information from PhosphoSitePlus (R), www.phosphosite.org. f7d f14 b21 e1d b88 WHIM9 xenograft has activating mutation in KRAS ae4 ee0 fa2 e06 a02 MOUSE:KG38 MOUSE fa2 mutations: E542K or E545K in exon 9, and H1047R or H1047L in exon 20 parentid=P35222; parentsymbol=CTNNB1; site=QQQsyLDsGIHsGAT; position=ser33; sitegrpid=447487; ptm=p; direction=u parent=P35222; parent=CTNNB1; site=yLDsGIHsGATtTAP; position=ser37; sitegrpid=447582; ptm=p; direction=u parentid=P35222; parentsymbol=CTNNB1; site=GIHsGATtTAPsLsG; position=thr41; sitegrpid=447583; ptm=p; direction=u parentid=Q02750; parentsymbol=MAP2K1; site=VsGQLIDsMANsFVG; position=ser218; sitegrpid=448514; ptm=p; direction=u parentid=Q02750; parentsymbol=MAP2K1; site=LIDsMANsFVGtRSY; position=ser222; sitegrpid=448513; ptm=p; direction=u parentid=P28482; parentsymbol=MAPK1; site=HtGFLtEyVAtRWyr; position=tyr187; sitegrpid=447594; ptm=p; direction=u parentid=P28482; parentsymbol=MAPK1; site=HDHtGFLtEyVAtRW; position=thr185; sitegrpid=447593; ptm=p; direction=u parentid=P27361; parentsymbol=MAPK3; site=HDHtGFLtEyVAtRW; position=thr202; sitegrpid=447542; ptm=p; direction=u parentid=P27361; parentsymbol=MAPK3; site=HtGFLtEyVAtRWyr; position=tyr204; sitegrpid=447543; ptm=p; direction=u parentid=P36507; parentsymbol=MAP2K2; site=VsGQLIDsMANsFVG; position=ser222; sitegrpid=448073; ptm=p; direction=u parentid=P36507; parentsymbol=MAP2K2; site=LIDsMANsFVGtRSY; position=ser226; sitegrpid=448074; ptm=p; direction=u dd7 28348404 PubMed Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun 2017 Huang KL Li S Mertins P Cao S Gunawardena HP Ruggles KV Mani DR Clauser KR Tanioka M Usary J Kavuri SM Xie L Yoon C Qiao JW Wrobel J Wyczalkowski MA Erdmann-Gilmore P Snider JE Hoog J Singh P Niu B Guo Z Sun SQ Sanati S Kawaler E Wang X Scott A Ye K McLellan MD Wendl MC Malovannaya A Held JM Gillette MA Fenyö D Kinsinger CR Mesri M Rodriguez H Davies SR Perou CM Ma C Reid Townsend R Chen X Carr SA Ellis MJ Ding L 17397528 PubMed FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007 Elbauomy Elsheikh S Green AR Lambros MB Turner NC Grainge MJ Powe D Ellis IO Reis-Filho JS Notch signaling pathway PW:0000204 Pathway Ontology 26028978 PubMed PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) 2015 Mukohara T 20453058 PubMed Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010 O'Brien C Wallin JJ Sampath D GuhaThakurta D Savage H Punnoose EA Guan J Berry L Prior WW Amler LC Belvin M Friedman LS Lackner MR 15805248 PubMed PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005 Saal LH Holm K Maurer M Memeo L Su T Wang X Yu JS Malmström PO Mansukhani M Enoksson J Hibshoosh H Borg A Parsons R disease pathway PW:0000013 Pathway Ontology 20570901 PubMed Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010 Hynes NE Dey JH phosphatidylinositol 3-kinase-Akt signaling pathway PW:0000232 Pathway Ontology 18676830 PubMed An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008 Stemke-Hale K Gonzalez-Angulo AM Lluch A Neve RM Kuo WL Davies M Carey M Hu Z Guan Y Sahin A Symmans WF Pusztai L Nolden LK Horlings H Berns K Hung MC van de Vijver MJ Valero V Gray JW Bernards R Mills GB Hennessy BT cancer pathway PW:0000605 Pathway Ontology 3798106 PubMed Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL 23220880 PubMed Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013 Bose R Kavuri SM Searleman AC Shen W Shen D Koboldt DC Monsey J Goel N Aronson AB Li S Ma CX Ding L Mardis ER Ellis MJ 25514926 PubMed PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 2015 Hornbeck PV Zhang B Murray B Kornhauser JM Latham V Skrzypek E 27251275 PubMed Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 2016 Mertins P Mani DR Ruggles KV Gillette MA Clauser KR Wang P Wang X Qiao JW Cao S Petralia F Kawaler E Mundt F Krug K Tu Z Lei JT Gatza ML Wilkerson M Perou CM Yellapantula V Huang KL Lin C McLellan MD Yan P Davies SR Townsend RR Skates SJ Wang J Zhang B Kinsinger CR Mesri M Rodriguez H Ding L Paulovich AG Fenyö D Ellis MJ Carr SA breast cancer pathway PW:0000624 Pathway Ontology cancer DOID:162 Disease